TSPSC AEE Hall Ticket

Syros Pharmaceuticals is in the healthcare sector and is in the biotechnology industry. The company CEO is Nancy A. Simonian. Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in the understanding of the region of the genome controlling the activation and repression of genes. The companies lead candidates are SY425 and SY365.



Previous Intraday Performance:

The SYRS shares had a previous change of -0.33% which opened at 6.01 and closed at 5.98. It moved to an intraday high of 6.15 and a low of 5.83.

Business Wire:  Syros Announces Appointment of Alice T. Shaw to its Board of Directors

Historical Performance:

Over the last five trading days, SYRS shares returned 0.34% and in the past 30 trading days it returned -12.57%. Over three months, it changed -9.12%. In one year it has changed -52.43% and within that year its 52 week high was 13.58 and its 52 week low was 5.17. SYRS stock is 15.67% above its 52 week low.

Our calculations result in a 200 day moving average of 7.83 and a 50 day moving average of 6.84. Right now, SYRS stock is trading -23.63% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

Business Wire:  Syros to Present at JMP Securities Life Sciences Conference

Liquidity:

The company has a market cap of $253.8m with 42.4m shares outstanding and a float of 40.7m shares. Trading volume was 70,417 shares and has experienced an average volume of 109,142 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Syros Pharmaceuticals was -1.92 which ended on 31st of December 2018. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.57.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 05-01-2019: -0.49
4thQtr 2018Reported 03-07-2019: -0.54
3rdQtr 2018Reported 11-01-2018: -0.47
2ndQtr 2018Reported 08-07-2018: -0.43
1stQtr 2018Reported 05-10-2018: -0.48

The growth of the EPS is critical in understanding the current valuation of Syros Pharmaceuticals; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 416.70% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 73.80% of institutional ownership.



The beta was calculated to be 1.23.

Business Wire:  Syros to Present at JMP Securities Life Sciences Conference

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -59.37%, price-to-sales is 119.31 and price-to-book is 3.98.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here